Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Prestige Consumer Healthcare (PBH)
:PBH
RESEARCH TOOLSreports
PBH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$62.35 - $88.36
Previous CloseN/A
Volume57.25K
Average Volume (3M)313.19K
Market Cap
$4.20B
Enterprise Value$4.88B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)19.8
Beta0.49
Next Earnings
May 01, 2025EPS Estimate
1.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.27
Shares Outstanding49,537,838
10 Day Avg. Volume330,102
30 Day Avg. Volume313,189
Standard Deviation0.07
R-Squared0.14
Alpha0.00722
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.76
Price to Cash Flow (P/CF)16.10
P/FCF Ratio15.30
Enterprise Value/Market Cap1.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.82
Enterprise Value/Ebitda13.70
Forecast
1Y Price Target
$96.75Price Target Upside14.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Prestige Consumer Healthcare News
PremiumCompany Announcements
Prestige Consumer Healthcare Reports Record Earnings Despite Challenges
PremiumCompany Announcements
Prestige Consumer Healthcare Reports Stable Earnings Growth
PremiumCompany Announcements
Prestige Consumer Healthcare Reports Q3 2024 Financial Growth---
Bulls Say, Bears Say
Bulls Say
Cash Flow And Financial HealthPBH continues to generate a significant amount of cash due to low-to-mid-30s EBITDA margins with a niche portfolio of self-care products with limited risk of trading down or being restocked.
EarningsPBH reported strong results with sales beating guidance, driven by international and North American strength.
Management StrategyThe appointment of Christine Sacco into a dual CFO/COO role could indicate PBH is looking closely at M&A and wants additional oversight on integrating any acquisition.
Bears Say
Margin ChallengesPrestige has peer-leading margins (33% EBITDA vs. 23% avg.), even though they are off-peak (-75bp vs. F19), indicating margin pressure.
Market ValuationWith valuation at an 18% premium to its 5Y avg., it is thought that MSD% EPS, better capital returns, and M&A potential are already factored in.
Portfolio Shift ConcernsShifting the portfolio mix away from needs-based towards more recurring categories could potentially limit additional multiple expansion.
---
Ownership Overview
1.18% Insiders
41.89% Mutual Funds
22.12% Other Institutional Investors
6.78% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PBH FAQ
What was Prestige Consumer Healthcare’s price range in the past 12 months?
Prestige Consumer Healthcare lowest stock price was $62.35 and its highest was $88.36 in the past 12 months.
What is Prestige Consumer Healthcare’s market cap?
Prestige Consumer Healthcare’s market cap is $4.20B.
When is Prestige Consumer Healthcare’s upcoming earnings report date?
Prestige Consumer Healthcare’s upcoming earnings report date is May 01, 2025 which is in 67 days.
How were Prestige Consumer Healthcare’s earnings last quarter?
Prestige Consumer Healthcare released its earnings results on Feb 06, 2025. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of $1.175 by $0.045.
Is Prestige Consumer Healthcare overvalued?
According to Wall Street analysts Prestige Consumer Healthcare’s price is currently Undervalued.
Does Prestige Consumer Healthcare pay dividends?
Prestige Consumer Healthcare does not currently pay dividends.
What is Prestige Consumer Healthcare’s EPS estimate?
Prestige Consumer Healthcare’s EPS estimate is 1.3.
How many shares outstanding does Prestige Consumer Healthcare have?
Prestige Consumer Healthcare has 49,537,838 shares outstanding.
What happened to Prestige Consumer Healthcare’s price movement after its last earnings report?
Prestige Consumer Healthcare reported an EPS of $1.22 in its last earnings report, beating expectations of $1.175. Following the earnings report the stock price went up 14.783%.
Which hedge fund is a major shareholder of Prestige Consumer Healthcare?
Currently, no hedge funds are holding shares in PBH
---
Prestige Consumer Healthcare Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$96.75 (14.32% Upside)
$96.75 (14.32% Upside)
Blogger Sentiment
Bullish
PBH Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 174.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $959.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.13%
12-Months-Change
Fundamentals
Return on Equity
12.63%
Trailing 12-Months
Asset Growth
-0.31%
Trailing 12-Months
Company Description
Prestige Consumer Healthcare
Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American OTC Healthcare, and International OTC Healthcare. The North American and International OTC Healthcare segments manages the following brands: BC/Goody's, Beano, Boudreaux's Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden's, Monistat, Nix, Pedia-Lax, and Summer's Eve. The company was founded in 1996 and is headquartered in Tarrytown, NY.
---
PBH Company Deck
---
PBH Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong quarterly performance with record sales and EPS, driven by international growth and improved financial health through debt reduction. However, challenges remain with declines in certain segments like Cough & Cold, supply chain constraints for Clear Eyes, and broader economic concerns such as tariffs and inflation.Read More>---
PBH Stock 12 Month Forecast
Average Price Target
$96.75
▲(14.32% Upside)
Technical Analysis
Church & Dwight
―
Colgate-Palmolive
―
Energizer Holdings
―
Johnson & Johnson
―
Kimberly Clark
―
Best Analysts Covering PBH
1 Year
1 Year Success Rate
11/12 ratings generated profit
1 Year Average Return
+16.67%
reiterated a buy rating 17 days ago
Copying Susan Anderson's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +16.67% per trade.
---